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Allergen Immunotherapy (AIT), is effective in reducing
the clinical symptoms associated with allergic rhinitis,
asthma and venom induced anaphylaxis [1]. Subcuta-
neous (SCIT) and Sublingual (SLIT) with unmodified
allergen extracts are the two routes of administration of
allergen vaccines.
In addition, AIT has been positioned as the only treat-
ment that may alter the natural course of allergic disease
[2]. However both SCIT and SLIT require that the treat-
ment is taken regularly over several years e.g. monthly in
a supervised medical setting with SCIT and at lowest
three times a week with SLIT. Emerging evidence sug-
gests that specific allergen immunotherapy may be effec-
tive in other allergic conditions such as IgE mediated
food allergy [3,4] and extrinsic form IgE mediated Atopic
Dermatitis [5]. On all these fields, the immunotherapy’s
triad can be an effective tool (Figure 1).
Moreover due to the complexity of IgE mediated disor-
ders, each component of triad: SCIT, SLIT or Oral Immu-
notherapy (OIT) could be considered as complementary
or synergic therapy. Currently, in paediatrics, the challenge
is represented by the possibility of defeat the reluctance to
encourage the implementation of early intervention in IgE
mediated allergic diseases, with the goal of achieving either
secondary prevention or long lasting benefit through
immunotherapy(ies) which is the only antigen specific
immunomodulatory treatment routinely available .These
effects are of particular relevance in paediatric population
with the aim of impairing the natural history of allergic
diseases.
The mechanisms of action of AIT have been elucidated:
a diminished allergen specific T-cell proliferation and sup-
pressed secretion of TH2 cell responses are the character-
istic hallmarks. In addiction, T regulatory (Treg) cells
inhibit the development of allergen specific TH2 and TH1
cell responses an therefore exert key roles in healthy
immune response to allergens. Treg cells potently sup-
press IgE production and directly or indirectly control the
activity of effectors cells of allergic inflammation, such as
eosinophils, basophils, and mast-cells [6].
Therefore, AIT in different forms represent an effective
therapeutic approach in children with IgE mediated
respiratory disorders. Moreover, in other allergic disorders
that are no part of the respiratory disease spectrum, the
evidence is beginning to emerge that these diseases also
will respond to allergen specific immunotherapy.
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Figure 1 The immunotherapy’s triad. The main routes and forms
of immunotherapy. Due to the complexity of IgE mediated
disorders the triad could be considered as complementary therapy.
Thus SCIT, SLIT and OIT could be used in various combination and
timing in order to optimize both adherence to treatment and
therapeutics effect. SCIT= subcutaneous immunotherapy for the
treatment of allergic asthma and allergic rhinitis. SLIT= sublingual
immunotherapy for the treatment respiratory allergies and IgE
mediated food allergies. OIT= oral immunotherapy for the active
treatment of IgE mediated food allergy. On the horizon: the
treatment of extrinsic form IgE mediated atopic dermatitis.
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